Preclinical candidates and targets for tuberculosis therapy.
Like many neglected diseases of the developing world, tuberculosis (TB) has a thin portfolio of new compounds currently in the discovery pipeline with near-term clinical potential. Co-development of broad-spectrum antibacterials for TB indications is superficially attractive but unlikely to result in significant advances in therapy. Genomic information has been useful in the redesign of second-line antituberculars such as ethambutol and such molecules will likely soon enter preclinical development. New targets and lead compounds with activity against the mycobacterial cell wall and non-replicating bacilli are the subject of current discovery programs.
Barry
C E
CE
Tuberculosis Research Secton, LHD, NIAID, NIH, Rockville, MD 20852, USA. clifton_barry@nih.gov
D000693:Anaerobiosis; D000995:Antitubercular Agents / Q000494:pharmacology*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism
D000995:Antitubercular Agents